Gintvile Valinciute, Jonas Ecker, Florian Selt, Thomas Hielscher, Romain Sigaud, Johannes Ridinger, Venu Thatikonda, Charlotte Gatzweiler, Sarah Robinson, Julie Talbot, Flavia Bernardi, Daniel Picard, Mirjam Blattner-Johnson, Simone Schmid, David T Jones, Cornelis M van Tilburg, David Capper, Marcel Kool, Marc Remke, Ina Oehme, Stefan M Pfister, Martine F Roussel, Olivier Ayrault, Olaf Witt, Till Milde
PURPOSE: We and others have demonstrated that MYC-amplified medulloblastoma (MB) cells are susceptible to class I histone deacetylase inhibitor (HDACi) treatment. However, single drug treatment with HDACi has shown limited clinical efficacy. We hypothesized that addition of a second compound acting synergistically with HDACi may enhance efficacy. METHODS: We used a gene expression dataset to identify PLK1 as a second target in MB cells and validated the relevance of PLK1 in MB...
May 15, 2023: Journal of Neuro-oncology